Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Buprenorphine

FDA-approved product (film, extended release, transdermal), marketed as Brixadi, Buprenorphine, Butrans and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Buprenorphine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic pain
  • Drug dependence
  • Opioid dependence
  • Opioid use disorder
  • Overdose
  • Pain
  • Substance abuse

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Oripavine derivatives; Drugs used in opioid dependence
FDA pharmacologic class
Partial Opioid Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Buprenorphine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not docked: the structure could not be prepared for dockingdetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not docked: the structure could not be prepared for dockingdetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not docked: the structure could not be prepared for dockingdetails

Dihydrofolate reductase ↗ (MRSA)

Not docked: the structure could not be prepared for dockingdetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Buprenorphine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine

    NCT07361432 · start 2026-11-02

    Registered record
    Registry ID
    NCT07361432
    Conditions
    Opioid Use Disorder; Chronic Pain
    Interventions
    Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT); Enhanced Treatment as Usual (ETAU)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11-02
    Completion
    2030-05-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Chronic Pain
    InterventionIntegrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT); Enhanced Treatment as Usual (ETAU)
    PhasePhase 3
    Registry statusNot yet recruiting

  • Buprenorphine for the Management of Pain in Children With Sickle Cell Disease

    NCT07799571 · start 2026-10

    Registered record
    Registry ID
    NCT07799571
    Conditions
    Sickle Cell Disease (SCD); Sickle Cell Disease Vaso-occlusive Crisis; Sickle Cell Anemia Crisis; Sickle Cell Anemia in Children; Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0); Sickle Cell Hemoglobin C Disease; Pain Crisis
    Interventions
    Buprenorphine Buccal Film [Belbuca]
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2032-10
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease (SCD); Sickle Cell Disease Vaso-occlusive Crisis; Sickle Cell Anemia Crisis; Sickle Cell Anemia in Children +3 more
    InterventionBuprenorphine Buccal Film [Belbuca]
    PhasePhase 1
    Registry statusNot yet recruiting

  • NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

    NCT06854029 · start 2026-09-01

    Registered record
    Registry ID
    NCT06854029
    Conditions
    HIV Infections; Opioid Use Disorder; Incarceration; Lens
    Interventions
    Cabotegravir Injection; Cabotegravir Pill; Buprenorphine injection; Buprenorphine Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2030-06-01
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Opioid Use Disorder; Incarceration; Lens
    InterventionCabotegravir Injection; Cabotegravir Pill; Buprenorphine injection; Buprenorphine Pill
    PhasePhase 4
    Registry statusNot yet recruiting

  • PRoducing Outcome Measures for OTP Quality Improvement

    NCT07214389 · start 2025-10-03

    Registered record
    Registry ID
    NCT07214389
    Conditions
    Opioid Use Disorder
    Interventions
    Quality Measures (Audit and Feedback); Quality Improvement (QI) Toolkit; External QI Facilitation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-10-03
    Completion
    2027-12-01
    Enrolment
    4,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder
    InterventionQuality Measures (Audit and Feedback); Quality Improvement (QI) Toolkit; External QI Facilitation
    PhaseNot applicable
    Registry statusRecruiting

  • Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects

    NCT06981195 · start 2025-05-27

    Registered record
    Registry ID
    NCT06981195
    Conditions
    Opioid Use Disorder; Opioid Use; Insomnia; Orexin Antagonist
    Interventions
    Placebo; Lemborexant 10 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-27
    Completion
    2029-07-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Opioid Use; Insomnia; Orexin Antagonist
    InterventionPlacebo; Lemborexant 10 MG
    PhasePhase 2
    Registry statusRecruiting

  • Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use

    NCT06379984 · start 2025-05-08

    Registered record
    Registry ID
    NCT06379984
    Conditions
    Opioid Use Disorder
    Interventions
    Buprenorphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-08
    Completion
    2027-06-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder
    InterventionBuprenorphine
    PhasePhase 2
    Registry statusRecruiting

  • Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail

    NCT06593353 · start 2024-11-21

    Registered record
    Registry ID
    NCT06593353
    Conditions
    Opioid Use Disorder; Opioid Use Disorders
    Interventions
    Systems Analysis and Improvement Approach (SAIA)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-11-21
    Completion
    2028-06-30
    Enrolment
    4,186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Opioid Use Disorders
    InterventionSystems Analysis and Improvement Approach (SAIA)
    PhaseNot applicable
    Registry statusRecruiting

  • Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington

    NCT06187064 · start 2024-03-18

    Registered record
    Registry ID
    NCT06187064
    Conditions
    Opioid Use Disorder; HIV Infections; Chlamydia; Gonorrhea; Syphilis; Trichomonas
    Interventions
    Mobile Van Clinic
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-03-18
    Completion
    2025-03-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; HIV Infections; Chlamydia; Gonorrhea +2 more
    InterventionMobile Van Clinic
    PhaseNot applicable
    Registry statusCompleted

  • Assessing Optimal XR-Buprenorphine Initiation Points in Jail

    NCT05481112 · start 2023-11-01

    Registered record
    Registry ID
    NCT05481112
    Conditions
    Opioid Use Disorder
    Interventions
    Extended-Release Buprenorphine Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2023-11-01
    Completion
    2026-02-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder
    InterventionExtended-Release Buprenorphine Injection
    PhasePhase 4
    Registry statusWithdrawn

  • Pain Care at Home to Amplify Function (Pain CHAMP)

    NCT05333341 · start 2023-06-16

    Registered record
    Registry ID
    NCT05333341
    Conditions
    Opioid Use Disorder; Opioid Misuse; Chronic Pain
    Interventions
    TCM; TCM plus COPES
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2023-06-16
    Completion
    2027-06-30
    Enrolment
    259

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Opioid Misuse; Chronic Pain
    InterventionTCM; TCM plus COPES
    PhaseNot applicable
    Registry statusActive not recruiting

  • Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD

    NCT05944133 · start 2023-03-29

    Registered record
    Registry ID
    NCT05944133
    Conditions
    Opioid Use Disorder; Opioid Overdose; Death
    Interventions
    No intervention, observational retrospective study
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2023-03-29
    Completion
    2026-02-28
    Enrolment
    27,257

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Opioid Overdose; Death
    InterventionNo intervention, observational retrospective study
    PhaseNot recorded
    Registry statusActive not recruiting

  • Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder

    NCT03787628 · start 2022-05-19

    Registered record
    Registry ID
    NCT03787628
    Conditions
    Opioid-use Disorder
    Interventions
    Cannabidiol (CBD) 600 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-05-19
    Completion
    2024-03-12
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-use Disorder
    InterventionCannabidiol (CBD) 600 mg; Placebo
    PhasePhase 2
    Registry statusCompleted

  • EXHIT ENTRE Comparative Effectiveness Trial

    NCT04345718 · start 2021-08-09

    Registered record
    Registry ID
    NCT04345718
    Conditions
    Substance Use Disorder; Opioid Use Disorder, Moderate; Opioid Use Disorder, Severe
    Interventions
    Extended Release Buprenorphine; Treatment as Usual
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-08-09
    Completion
    2025-08-27
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubstance Use Disorder; Opioid Use Disorder, Moderate; Opioid Use Disorder, Severe
    InterventionExtended Release Buprenorphine; Treatment as Usual
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Emergency Department-Initiated Buprenorphine Validation Network Trial

    NCT04225598 · start 2020-07-08

    Registered record
    Registry ID
    NCT04225598
    Conditions
    Opioid-use Disorder
    Interventions
    CAM2038; Buprenorphine Sublingual Product
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-07-08
    Completion
    2024-12-06
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-use Disorder
    InterventionCAM2038; Buprenorphine Sublingual Product
    PhasePhase 2
    Registry statusCompleted

  • Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants

    NCT03845894 · start 2020-03-03

    Registered record
    Registry ID
    NCT03845894
    Conditions
    Shoulder Arthroplasty
    Interventions
    Liposomal bupivacaine; Bupivacaine with adjuvants
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2020-03-03
    Completion
    2022-06-25
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShoulder Arthroplasty
    InterventionLiposomal bupivacaine; Bupivacaine with adjuvants
    PhasePhase 4
    Registry statusTerminated